Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Social Media Representation of Chronic Cerebrospinal Venous Insufficiency Intervention for Multiple Sclerosis.
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
Multiple sclerosis: association with HL-A3.
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients.
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE))
CHMP issues positive opinion for TECFIDERA™ (dimethyl fumarate) as a first-line treatment for multiple sclerosis in the European Union
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA TM*) in Multiple Sclerosis
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis.
Timing of birth and risk of multiple sclerosis: population based study.
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Overview of the immune system.
Diplomatic Assistance: Can Helminth-Modulated Macrophages Act as Treatment for Inflammatory Disease?
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.
Autoimmune sleep disorders.
Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD.
Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.
Perk Ablation Ameliorates Myelination in S63del-Charcot-Marie-Tooth 1B Neuropathy.
10 years of interferon beta-1b (Beta feron therapy.
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids.
Newly onset sinus bradycardia in the context of multiple sclerosis relapse.
Policy: NIH to balance sex in cell and animal studies.

Pages